Innovative breast cancer screening2D and 3D mammography may miss cancers in dense breasts 1, 2, potentially delaying diagnosis in these women. Both dense breast tissue and cancer appear white on a mammogram, creating a dangerous camouflage effect and a dilemma for radiologists whose goal is to find breast cancer as early as possible.
Improve breast cancer detectionMammography may miss over 1/3 of cancers in dense breasts.1 The InveniaTMABUS 2.0 (Automated Breast Ultrasound System) is a comfortable, nonionizing alternative to other supplemental screening options for women with dense breast tissue. When used in addition to mammography, Invenia ABUS 2.0 can improve breast cancer detection by 37.5 percent over mammography alone.2 Learn more about Invenia ABUS 2.0 by downloading the brochure.
Why is Invenia ABUS 2.0 screening needed?Approximately 40% of women have dense breasts 4, one of the strongest common risk factors for developing breast cancer 5. Having dense breasts increases a woman's chance of developing breast cancer by four to six times 6, and seventy-one percent of breast cancers are found in dense breasts. 7 Learn more about breast density by downloading a breast density informational sheet.
Invenia ABUS 2.0 can improve early detection
Clinical evidence is growing about the effectiveness of ultrasound for finding small, node-negative, invasive cancers missed by mammography. Invenia ABUS 2.0 supplemental imaging is designed for the screening environment, specifically for dense breast imaging. Invenia ABUS 2.0 diminishes operator variability and creates 3D ultrasound volumes to enable comprehensive analysis and comparison to multimodality exams.
Download our case studies detailing how ABUS helped uncover hidden cancers below.
Read the SomoInsight Study to learn about the effectiveness of ABUS for supplemental breast screening.
Cancer detection improves for women with dense breasts when Automated Breast Ultrasound screening is combined with 3D tomosynthesis.
Mammography plus Automated Breast Ultrasound (ABUS) results can improve earlier detection of breast cancer.
Commercial reimbursement and utilization for Invenia ABUS (Automated Breast Ultrasound).
Real World Experience and Outcomes with Invenia ABUS Imaging For Women.
Real World Experience and Outcomes with Invenia ABUS at Fort Jesse's Imaging Center and Gale Keeran Center for Women
Developing a personalized breast screening program
Dr. Joseph Russo, Section Chief of Women's Imaging, St. Luke's University Health Network, Bethlehem, PALearn More
Dense breast tissue: Status of ultrasound for breast cancer screening
Marc F Inciardi, MD, Assistant Professor of Radiology, Section Head, Breast Imaging, University of Kansas Medical CenterLearn More
Implementation of ABUS in the community setting
Monica H Saini MD, MS, Breast RadiologistLearn More
Ian Grady MD, FACS, North Valley Breast Center, Redding, CALearn More
Automated breast sonographic coronal imaging: Diagnostic and screening applications
Beverly E Hashimoto, MD, FACR, Section Head, Ultrasound, Virginia Mason Medical Center, Seattle, WALearn More
Introduction to Automated Breast Ultrasound Screening women with dense breasts
Dr. Monica Saini, MD, CMO for Institute of Women’s Imaging and Medical Director for ABUS at GE HealthcareLearn More
Case review and clinical discussion of the clinical effectiveness of 3D ABUS at ECR 2018
Athina D. Vourtsis MD, PhD, Director and Founder of Diagnostic Mammography Center, Athens, GreeceLearn More
Breast anatomy, 2D, 3D, and Automated Breast Ultrasound
Mary Henne, MS, CNMT, RDMS, RVT, Clinical Research Education Leader - ABUS and Beverly E Hashimoto, M.D., FACR, Section Head, Ultrasound, Virginia Mason Medical Center, Seattle, WALearn More
What are clinicians and patients saying about their experience with ABUS?
Technology designed for screening
GE Healthcare is the sole provider of FDA-approved ultrasound technology for use as a supplemental screening for women with dense breast tissue. From its remarkable architecture to its advanced imaging algorithms, Invenia ABUS 2.0 is engineered for automated screening. Besides increased detection, the Invenia ABUS 2.0 is designed for reproducibility, ease of use, and both patient and operator comfort.
Invenia ABUS 2.0 uses the powerful cSound™ Imageformer, a software-based graphics processor, that provides a repeatable and operator-independent acquisition method to achieve consistent, high-quality results. cSound imaging allows significantly more data to be collected and used to create every image. Traditional hand-held ultrasound parameters such as focal zones and gain are automatically optimized. Because no image manipulation is required, high image quality is consistent from operator to operator with the touch of a button.
Intelligent imaging algorithms
Advanced algorithms automate the imaging process to help provide remarkable image quality and reproducibility from user to user, including: tissue equalization, nipple shadow compensation, breast border detection and chest wall detection. These are all designed to eliminate the distractions, and focus the radiologist's attention on the most important data - the anatomy.
Comfort for operators and patients
The gentle shape of the Reverse Curve™ transducer follows the natural contour of the breast, providing patient comfort, even compression and full contact and helps ensure comprehensive coverage. Since no two women are identical, exams can be customized with programmable scan protocols, adjustable scan depths, and compression levels. The operator can also shorten scan time once breast tissue acquisition is complete.
Intuitive and streamlined reading
The Invenia Viewer is designed for fast, efficient workflow for reading and reporting, allowing radiologists to quickly review, interpret and archive patient exams. Based on Windows®10 and powerful processing, the Invenia Viewer incorporates intuitive user interface icons and multiple viewing and hanging protocols, which can be customized by the user.
Invenia Viewer also provides the coronal view, which acts as a roadmap for evaluating the entire breast. This global perspective offers better visualization of architectural distortions and multifocal disease. Reconstructed 2-mm-thick coronal slices display constant orientation and location from the nipple, making it easy to evaluate the breast from the skin line to the chest wall. Correlations with other projections and planes are easily achieved.
Our dedicated support team is available to help you implement your ABUS program and make it a success. Users receive guidance and best practices, including real-world samples and professionally designed templates. Users also receive recommendations for educating key audiences, workflow options and marketing strategies help you launch your ABUS program.
Invenia ABUS 2.0 system consumable supplies
GE Healthcare offers an array of consumable supplies for the Invenia™ ABUS 2.0 and somo•v™ ABUS (Automated Breast Ultrasound) Platinum systems including scan membranes, Polysonic® ultrasound lotions, and Protex™ disinfectants. For a complete list of ABUS 2.0 accessories, visit: www.services.gehealthcare.com
GE Healthcare's AssurePoint Service offering helps enhance the overall total value of ownership of your Invenia ABUS 2.0.
Early detection of breast cancer enables treatment to be started earlier in the course of the disease, possibly before it has spread. Encourage your patients with dense breasts to advocate for their health and learn more about ABUS. Use the GE Healthcare ABUS Locator tool to find a facility in their area, and direct them to the website, pamphlet and video below.
GE Healthcare is pleased to offer providers coding and reimbursement support:
Toll-free phone number: 1-844-386-0099
Visit our reimbursement website
GE Healthcare agrees to abide by the provisions of the Health Insurance Portability and Accountability Act of 1996 (HIPAA) and any other relevant state or federal privacy laws and regulations concerning the use and/or disclosure of protected health information during the course of providing this support. CPT CODES are copyrighted by the American Medical Association.
1. Mandelson et al. J Natl Cancer Inst 2000; 92:1081–1087.
2. Tagliafico, Massimo Calabrese et al, Journal of Clinical Oncology 2016 34:16, 1882-1888.
3. Brem et al, Radiology, March 2015.
4. Pisano et al. NEJM 2005; 353: 1773.
5. Engmann NJ, et al, JAMA Oncol. 2017;3(9):1228-1236
6. Boyd NF et al. Mammographic Density and the Risk and Detection of Breast Cancer. NEJM 2007; 356: 227-36.
7. Arora N, King TA, Jacks LM., Ann Surg Onc, 2010; 17:S211-18.